Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-03-20

Clinical Trial Update: Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus [Phase 2]

View source ↗

Summary

This Phase 2 long-term safety and efficacy study of deucravacitinib in systemic lupus erythematosus has completed data collection and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Deucravacitinib (deucravacitinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: COMPLETED | Results posted: 2026-03-20